Cargando…

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study

BACKGROUND: Regorafenib improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we report the treatment patterns of regorafenib in the third- or late-line setting for mCRC in four centers in China. PATIENTS AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Donghao, Liu, Yu, Tang, Wentao, Xu, Lingsha, Liu, Tianyu, Jiang, Yudong, Zhou, Shizhao, Qin, Xiaorui, Li, Jisheng, Zhao, Jiemin, Ye, Lechi, Chang, Wenju, Xu, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007238/ https://www.ncbi.nlm.nih.gov/pubmed/35433423 http://dx.doi.org/10.3389/fonc.2022.838870

Ejemplares similares

The m6A RNA Modification Quantity and the Prognostic Effect of Reader YTHDC2 in Colorectal Cancer
por: Liu, Tianyu, et al.
Publicado: (2022)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
por: Li, Jisheng, et al.
Publicado: (2020)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
por: Dane, Faysal, et al.
Publicado: (2020)

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
por: Hendlisz, Alain, et al.
Publicado: (2015)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study
por: Dai, Xuan, et al.
Publicado: (2023)

Regorafenib Prior to Selective Internal Radiation Therapy Using (90)Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry, and Molecular Markers
por: Kennedy, Andrew, et al.
Publicado: (2019)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study
por: Zhou, Shizhao, et al.
Publicado: (2023)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Zhou, Hong, et al.
Publicado: (2021)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
por: Aydin, Sabin Goktas, et al.
Publicado: (2023)

Anatomical Resection Improves Disease-Free Survival After Lung Metastasectomy of Colorectal Cancer
por: Liu, Tianyu, et al.
Publicado: (2021)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Small Nuclear Ribonucleoprotein Polypeptide N Accelerates Malignant Progression and Poor Prognosis in Colorectal Cancer Transcriptionally Regulated by E2F8
por: Ji, Meiling, et al.
Publicado: (2020)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China
por: Ma, Yue, et al.
Publicado: (2023)

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
por: Lin, Chun-Yu, et al.
Publicado: (2018)

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
por: Clarke, Jeffrey Melson, et al.
Publicado: (2019)

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
por: Fogelman, David, et al.
Publicado: (2018)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
por: Xu, Jianming, et al.
Publicado: (2020)

Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness
por: Xu, Yu-Jie, et al.
Publicado: (2022)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
por: Salvatore, Lisa, et al.
Publicado: (2023)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tcrq6bbu0fnrflttgnlgi1e08j